SCHEMBL4309870

SCHEMBL4309870

CCC(Cl)=NO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1106844 1.00
SCHEMBL10905365 0.73
SCHEMBL10905362 0.73
SCHEMBL13845856 0.71
SCHEMBL24130763 0.69
SCHEMBL23608562 0.67
SCHEMBL262790 0.65
SCHEMBL17000143 0.65
SCHEMBL24408784 0.65
SCHEMBL21490709 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116768811-B Method for preparing topramezone intermediate 帕潘纳(北京)科技有限公司 2025-04-11 CN claimed
CN-116768811-A Method for preparing topramezone intermediate 帕潘纳(北京)科技有限公司 2023-09-19 CN claimed
CN-116768811-B Method for preparing topramezone intermediate 帕潘纳(北京)科技有限公司 2025-04-11 CN disclosed
CN-116768811-B Method for preparing topramezone intermediate 帕潘纳(北京)科技有限公司 2025-04-11 CN disclosed
US-20250115620-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2025-04-10 US disclosed
EP-4438123-A2 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF Gilead Sciences, Inc. (US) 2024-10-02 EP disclosed
US-12054496-B2 Bridged tricyclic carbamoylpyridone compounds and uses thereof GILEAD SCIENCES, INC. (US) 2024-08-06 US disclosed
EP-4310087-B1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF GILEAD SCIENCES INC (US) 2024-07-03 EP disclosed
US-12024528-B2 Bridged tricyclic carbamoylpyridone compounds and uses thereof GILEAD SCIENCES, INC. (US) 2024-07-02 US disclosed
EP-4305034-B1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF GILEAD SCIENCES INC (US) 2024-06-12 EP disclosed
EP-4310087-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF Gilead Sciences, Inc. (US) 2024-01-24 EP disclosed
EP-3134396-B1 AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NOVARTIS AG (CH) 2019-09-18 EP disclosed
WO-2019034700-A1 NOVEL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-02-21 WO disclosed
US-10112926-B2 Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors NOVARTIS AG (CH) 2018-10-30 US disclosed
EP-3134396-A1 AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS Novartis AG (CH) 2017-03-01 EP disclosed
US-20170037032-A1 AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NOVARTIS AG (CH) 2017-02-09 US disclosed
WO-2015162456-A1 AMINO PYRIDINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NOVARTIS AG (CH) 2015-10-29 WO disclosed
US-20090312356-A1 NICOTINIC AGONISTS SELECTIVE FOR THE ALPHA7 RECEPTOR SUBTYPE, THE PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREFROM UNIVERSITA DEGLI STUDI DI MILANO (IT) 2009-12-17 US disclosed
EP-2038281-A2 NICOTINIC AGONISTS SELECTIVE FOR THE ALPHA7 RECEPTOR SUBTYPE, THE PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREFROM Universita' degli Studi di Milano (IT) 2009-03-25 EP disclosed
WO-2008000469-A2 NICOTINIC AGONISTS SELECTIVE FOR THE ALPHA7 RECEPTOR SUBTYPE, THE PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREFROM UNIVERSITA DEGLI STUDI DI MILANO (IT) 2008-01-03 WO disclosed